From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development
- PMID: 17346104
- DOI: 10.2174/156800907780058862
From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development
Abstract
The current field of oncolytic virus development has evolved from, and been educated by, the route adenoviruses have taken to Phase III development in the United States (Onyx-015) and commercial approval in China (H101). Clinical development of these E1B-deleted viruses showed that a staged approach, from single-agent intratumoral injections to trials testing intravenous delivery and trials in combination with approved therapies is judicious and can be successful. Additional oncolytic products are in development, including andenovirus plus other promising platforms such as herpes simplex virus, Newcastle disease virus, reovirus and vaccinia virus. These second-generation products seek to expand clinical utility beyond the modest local efficacy of Onyx-015/H101 to potent systemic delivery and efficacy. Improvement of efficacy in metastatic cancer will depend not only on enhanced killing of tumor cells, but also on achieving intravenous delivery and better intratumoral dissemination. Many viruses inherently replicate preferentially in tumors, and engineering can increase this therapeutic index by targeting genetic features of cancers. However, both viruses and cancer cells have complex biologies. Therefore, research may reveal that there is not a single predictive factor for tumor specificity. For example, the Onyx-015 mechanism-of-selectivity has proved to be complex. Further research regarding pathway dependence for other oncolytic viruses may also reveal multiple influences on their tumor tropism.
Similar articles
-
Clinical trials with oncolytic adenovirus in China.Curr Cancer Drug Targets. 2007 Mar;7(2):141-8. doi: 10.2174/156800907780058817. Curr Cancer Drug Targets. 2007. PMID: 17346105 Review.
-
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.Gene Ther. 2005 Sep;12(17):1333-46. doi: 10.1038/sj.gt.3302555. Gene Ther. 2005. PMID: 15920462
-
Clinical development directions in oncolytic viral therapy.Cancer Gene Ther. 2011 May;18(5):305-17. doi: 10.1038/cgt.2011.7. Epub 2011 Mar 25. Cancer Gene Ther. 2011. PMID: 21436867 Review.
-
Advances in oncolytic viral therapy.Curr Opin Investig Drugs. 2006 Jun;7(6):549-59. Curr Opin Investig Drugs. 2006. PMID: 16784026 Review.
-
Oncolytic Replication of E1b-Deleted Adenoviruses.Viruses. 2015 Nov 6;7(11):5767-79. doi: 10.3390/v7112905. Viruses. 2015. PMID: 26561828 Free PMC article. Review.
Cited by
-
Synergistic interaction between oncolytic viruses augments tumor killing.Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16. Mol Ther. 2010. PMID: 20234341 Free PMC article.
-
Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.J Oncol. 2010;2010:736907. doi: 10.1155/2010/736907. Epub 2010 Jun 23. J Oncol. 2010. PMID: 20631910 Free PMC article.
-
Increasing the efficacy of oncolytic adenovirus vectors.Viruses. 2010 Sep;2(9):1844-1866. doi: 10.3390/v2091844. Epub 2010 Aug 27. Viruses. 2010. PMID: 21994711 Free PMC article.
-
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.Cochrane Database Syst Rev. 2015 Dec 1;2015(12):CD010341. doi: 10.1002/14651858.CD010341.pub2. Cochrane Database Syst Rev. 2015. PMID: 26625332 Free PMC article. Review.
-
A dual-regulated oncolytic adenovirus carrying TAp63 gene exerts potent antitumor effect on colorectal cancer cells.Am J Transl Res. 2017 Jun 15;9(6):2966-2974. eCollection 2017. Am J Transl Res. 2017. PMID: 28670384 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources